Inhibition of histone deacetylases in inflammatory bowel diseases. - Wikidata - awgldk - TriplyDB

Inhibition of histone deacetylases in inflammatory bowel diseases.

Inhibition of histone deacetylases in inflammatory bowel diseases.

http://www.wikidata.org/entity/Q37848684

about

Fibrogenesis and fibrosis in inflammatory bowel diseases: Good and bad side of same coin?Shining a light on intestinal traffic Repeated predictable stress causes resilience against colitis-induced behavioral changes in mice Identification of novel compounds that enhance colon cancer cell sensitivity to inflammatory apoptotic ligands.Histone deacetylase inhibitors for treating a spectrum of diseases not related to cancer Small-molecule control of cytokine function: new opportunities for treating immune disorders Histone/protein deacetylases and T-cell immune responses Cooperation between the bacterial-derived short-chain fatty acid butyrate and interleukin-22 detected in human Caco2 colon epithelial/carcinoma cells.Regulation of intestinal serotonin transporter expression via epigenetic mechanisms: role of HDAC2.The epigenetic effects of aspirin: the modification of histone H3 lysine 27 acetylation in the prevention of colon carcinogenesis in azoxymethane- and dextran sulfate sodium-treated CF-1 mice.Beyond gene discovery in inflammatory bowel disease: the emerging role of epigenetics.Class I and II histone deacetylase inhibition by ITF2357 reduces SLE pathogenesis in vivo.Modulation of antigen-presenting cells by HDAC inhibitors: implications in autoimmunity and cancer.Linking immunity, epigenetics, and cancer in inflammatory bowel disease.Review article: selective histone deacetylase isoforms as potential therapeutic targets in inflammatory bowel diseases.Histone deacetylase 5 regulates the inflammatory response of macrophages.Inhibition of multiple pathogenic pathways by histone deacetylase inhibitor SAHA in a corneal alkali-burn injury model.Acute sensitization of colon cancer cells to inflammatory cytokines by prophase arrest Dietary inhibitors of histone deacetylases in intestinal immunity and homeostasis Histone deacetylase-mediated regulation of the antimicrobial peptide hBD2 differs in intestinal cell lines and cultured tissue Histone Deacetylases Enhance Ca-Activated K⁺ Channel K3.1 Expression in Murine Inflammatory CD4⁺ T Cells

P2860

Q26859968-C59438EF-BBDA-44FD-9D62-BBDB154B1C9B Q26863227-D1465120-40E0-4F0A-BFFC-8A8A2463BC83 Q34462522-489B17B1-CB07-4482-8599-E72027861766 Q34573226-564F1B85-55CF-4671-9CA3-578F1DFCD7A2 Q35016934-6DFC10B6-A196-4009-93DA-636E5AD22B59 Q35252669-264E6D31-9471-4E08-AB56-8108F96456EC Q35849307-2C220CE7-FF01-4415-85EE-C30CB693F8B5 Q36179133-88F9E1FA-C481-4D2A-A458-8460CD9F92B8 Q36593231-90FBF65F-297D-4C28-9669-70B884ADCE88 Q37220262-F6426F7D-0963-42A9-AD5F-B34763E145CD Q37572837-B7AD45D6-73CB-4577-B41D-32FF1EAA1F60 Q37657613-44DDA6FF-2905-4AE2-9E3C-E56F8E8C2601 Q37959304-6B7D2CE2-E1D3-4768-8369-493821202F88 Q38217532-FA53CEAA-705C-45C4-8AF6-0FC383E84C88 Q38264859-44FDD2FA-2D15-41B3-96BD-326B5D7A7146 Q41172414-342C27AE-49C4-403D-AA65-7AD8ED4C0791 Q41454864-F9E1712B-2F5E-4E07-9CC2-2D276CFEBFA1 Q42110300-1247CA10-F861-4040-81E7-BF405EF59572 Q42234572-7F87AD2A-B78F-4A50-94CE-8E7D35413D2D Q58701247-A8671D0E-25B9-4015-A6F7-CE71FF8FE13D Q59138318-28954370-D364-41C6-9BB4-12B585CDB063

P2860

Inhibition of histone deacetylases in inflammatory bowel diseases.

http://www.wikidata.org/entity/Q37848684

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 22 February 2011

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Inhibition of histone deacetylases in inflammatory bowel diseases.

@en

Inhibition of histone deacetylases in inflammatory bowel diseases.

@nl

type

label

Inhibition of histone deacetylases in inflammatory bowel diseases.

@en

Inhibition of histone deacetylases in inflammatory bowel diseases.

@nl

prefLabel

Inhibition of histone deacetylases in inflammatory bowel diseases.

@en

Inhibition of histone deacetylases in inflammatory bowel diseases.

@nl

P1433

Q37848684-5127B8BF-3158-4FA6-86E1-F9F61A211BBE

P1476

Q37848684-CFF44D48-29FE-4588-9A56-46EB720F011D

P2093

Q37848684-CF419D23-7A8E-47B9-A4B4-1B678677E64C

P2860

Q37848684-00010C4D-D80D-44CB-A538-22B8928E323C

Q37848684-00506257-8781-46AF-8222-1B3A023DEAAB

Q37848684-0354A7B4-B6C9-4C2A-9C79-4364AB3F624D

Q37848684-04ECCC50-C9D8-4540-AFE5-453989B60858

Q37848684-091AE5F3-1CC4-4A9E-8956-BB4B49CA9BA7

Q37848684-0993D104-1206-4BA2-A2F0-B61629F66932

Q37848684-0B22EF3A-1ECC-4ED0-9E57-2629BEAED625

Q37848684-0FF7002B-458B-4F51-A5BE-0CF0E85CBB44

Q37848684-105B9BCB-DF0F-4251-B42E-C114F24664D9

Q37848684-10DFA450-8285-4987-890F-CD2610483BD0

P2888

Q37848684-8F460887-2E59-4BC4-AC42-E250EEA65FD8

P304

Q37848684-05A41E73-6E85-4484-86ED-64DF417F3AAF

P31

Q37848684-30099FC1-B51D-4A25-B856-EED391BA057E

P356

Q37848684-FC87056A-F8E1-452C-A4D1-E27A32CE7432

P407

Q37848684-65EA752A-6546-42B0-A4C8-E4D45F8C4D18

P433

Q37848684-A2467F28-88CC-4553-B28B-38F1109BB895

P478

Q37848684-54AF9BDE-EE10-4F9D-9C1E-3B24706A08DF

P50

Q37848684-ECC36320-0B5D-4194-BBAE-EB87D4D3BF9E

P577

Q37848684-DEC60E38-09FA-427D-B292-9B35C536C847

P5875

Q37848684-C258CE16-0F90-48A8-ACE6-949CB9D22F28

P6179

Q37848684-9E57E431-E9F0-404C-B8A4-E255AE52BB76

P698

Q37848684-6929509E-83D1-4AD6-BCC7-4534048454AB

P921

Q37848684-9AB84908-AFD6-4B1A-8FE9-7B6AE9ECF00F

Q37848684-DED59D44-11B4-48F9-B432-35501632FEFA

P932

Q37848684-71A0D374-1DAC-445F-B9BF-E9DFA032ABD8

P356

MOLMED.2011.00069

P1433

Molecular Medicine

P1476

Inhibition of histone deacetylases in inflammatory bowel diseases.

@en

P2093

Rainer Glauben

http://www.w3.org/2001/XMLSchema#string

P2860

Molecular and therapeutic potential and toxicity of valproic acid

Three proteins define a class of human histone deacetylases related to yeast Hda1p

Histone deacetylase inhibition modulates indoleamine 2,3-dioxygenase–dependent DC functions and regulates experimental graft-versus-host disease in mice

The p65 (RelA) subunit of NF-kappaB interacts with the histone deacetylase (HDAC) corepressors HDAC1 and HDAC2 to negatively regulate gene expression

The MeCP1 complex represses transcription through preferential binding, remodeling, and deacetylating methylated nucleosomes

Interaction of GATA-3/T-bet transcription factors regulates expression of sialyl Lewis X homing receptors on Th1/Th2 lymphocytes

The histone deacetylase inhibitor Trichostatin A modulates CD4+ T cell responses

Lysine acetylation targets protein complexes and co-regulates major cellular functions

Post-activation turn-off of NF-kappa B-dependent transcription is regulated by acetylation of p65

Duration of nuclear NF-kappaB action regulated by reversible acetylation

P2888

molmed.2011.00069

P304

426-433

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2119/MOLMED.2011.00069

http://www.w3.org/2001/XMLSchema#string

P407

P433

5-6

http://www.w3.org/2001/XMLSchema#string

P478

17

http://www.w3.org/2001/XMLSchema#string

P50

Britta Siegmund

P577

2011-02-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

50251037

http://www.w3.org/2001/XMLSchema#string

P6179

1068965378

http://www.w3.org/2001/XMLSchema#string

P698

21365125

http://www.w3.org/2001/XMLSchema#string

P921

inflammatory bowel diseases

P932

3105130

http://www.w3.org/2001/XMLSchema#string